Journal: Heliyon
Article Title: Factors associated with increased risk of lurasidone-induced somnolence: Two case-control studies based on one bioequivalence trial in healthy volunteers
doi: 10.1016/j.heliyon.2023.e17905
Figure Lengend Snippet: Mean plasma concentration-time curves of lurasidone in the somnolence (n = 30 volunteers) and no-somnolence (n = 29 volunteers) groups of the first case-control study.
Article Snippet: The bioequivalence study was a randomized, two-way crossover, single-dose, two-period study to evaluate the bioavailability of two lurasidone hydrochloride tablets (40 mg): a test preparation manufactured by a domestic company and a reference preparation (Latuda®) manufactured by Sumitomo Dainippon Pharma Co., Ltd.
Techniques: Clinical Proteomics, Concentration Assay, Control